LOGIN  |  REGISTER
Viking Therapeutics
Amneal Pharmaceuticals

Becton Dickinson Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment

July 07, 2025 | Last Trade: US$172.95 3.21 -1.82

FRANKLIN LAKES, N.J., July 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that, effective July 2, Bilal Muhsin has been named executive vice president and will become the president of BD's future Connected Care segment, as part of the company's previously announced plans to update its structure as it advances its New BD strategy. Mushin will serve as a member of the BD Executive Leadership Team reporting to Tom Polen, chairman, CEO and president of BD and will lead the strategy development to support an effective transition into this new structure over the next several months.

Bilal Muhsin Joins BD as EVP and President of Future Connected Care Segment

Under Bilal's leadership, BD Connected Care will aim to leverage advanced analytics and AI solutions alongside BD's industry-leading smart devices to improve the efficiency and effectiveness of patient care while driving compelling growth opportunities in new areas of health care, such as connected medication management, advanced workflow robotics and smart monitoring solutions. In this newly created role, Muhsin will be responsible for advancing BD's future Connected Care strategy, including shaping organizational capabilities, driving and executing the commercial strategy, accelerating industry-leading innovation initiatives, and ensuring operational and quality excellence.

"With his extensive and deep knowledge of connected care technologies, software and informatics strategies, combined with his intense focus on the customer, Bilal will have a profound impact at BD as we advance our connected care strategy with cutting-edge, AI-driven technology that transforms patient care by improving safety, efficiency and outcomes," said Polen. "This is another step forward in advancing our New BD strategy as a differentiated, pure-play MedTech leader, and Bilal will play a critical role in helping BD accelerate our growth and impact on healthcare by capitalizing on the significant digital, robotic and AI technology innovation that we are so well-positioned to capitalize on."   

Muhsin joins BD from Masimo, a health technology and consumer electronics manufacturer, where he spent 25 years, most recently as chief operating officer. Prior to that, Bilal held several other leadership roles at Masimo, including executive vice president of engineering, marketing and regulatory. Muhsin has decades of experience with a proven track record in medical engineering and software development, and holds more than 50 patents in Medical Systems Communication, Analytics and Patient Monitoring Systems.

Muhsin holds a Bachelor of Science degree in Computer Science from San Diego State University.

About BD 

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.  

Contacts:

 

Media:

Investors:

Fallon McLoughlin

Adam Reiffe

BD Corporate Communications

BD Investor Relations

201.258.0361

201.847.6927

This email address is being protected from spambots. You need JavaScript enabled to view it.

This email address is being protected from spambots. You need JavaScript enabled to view it.

 
C4 Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page